Scalper1 News
Biotech Isis Pharmaceuticals leapt 10% to a new high above 68 Monday after it signed a licensing deal with Johnson & Johnson worth up to $835 million. Johnson & Johnson’s (JNJ) Janssen Biotech arm agreed to pay $35 million upfront and up to $800 million in milestone payments to develop drugs for autoimmune disorders of the gastrointestinal tract using Isis’ RNA-targeting platform. Such GI disorders have already filled Janssen’s coffers with drugs Scalper1 News
Scalper1 News